“…Spanish clinical guidelines recommend to perform a genotypic drug resistance test before starting antiretroviral therapy (ART) in all HIV-1-diagnosed patients and in ART-failing cases [ AIDS study group (GESIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology and the National AIDS Plan, 2020 ]. Pr-RT sequences obtained for these tests have been analyzed in different molecular epidemiology studies, describing the genetic features of the HIV-1 epidemic in different regions of Spain ( Thomson et al, 2001 ; Holguín et al, 2007 ; Cuevas et al, 2009a , b ; González-Alba et al, 2011 ; Yebra et al, 2013 ; Pérez-Parra et al, 2015 , 2016 ; Patiño-Galindo et al, 2016 , 2017b ; González-Domenech et al, 2020 ). The phylogenetic studies have also allowed the identification of large TCs among MSM which are actively growing in Spain ( Delgado et al, 2015 , 2019 ; Patiño-Galindo et al, 2017a ; González-Domenech et al, 2018 ), as well as transmitted drug resistance mutations which are spreading in TCs ( Cuevas et al, 2009b ; Vega et al, 2015 ; Viciana et al, 2016 ; González-Domenech et al, 2018 , 2020 ), highlighting the value of molecular epidemiology as a tool for HIV surveillance.…”